Time trends in hospital admissions for bronchiectasis: Analysis of the Spanish national hospital discharge data (2004 to 2013)

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Sánchez Muñoz, Gema ^a   De Andrés, Ana López ^b   Jiménez García, Rodrigo ^b   Carrasco Garrido, Pilar ^b   Hernández Barrera, Valentín ^b   Pedraza Serrano, Fernando ^a   Puente Maestu, Luis ^a   De Miguel Díez, Javier ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRONCHIECTASIS; CHARLSON COMORBIDITY INDEX; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL MORTALITY; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PSEUDOMONAS INFECTION; SEX DIFFERENCE; TOBACCO CONSUMPTION; TREND STUDY; VERY ELDERLY; ECONOMICS; HEALTH CARE COST; HOSPITAL DISCHARGE; HOSPITALIZATION; MIDDLE AGED; SPAIN; TIME FACTOR; TRENDS;

ADULT; AGED; AGED, 80 AND OVER; BRONCHIECTASIS; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT DISCHARGE; SPAIN; TIME FACTORS;

EID: 84991106594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162282     Document Type: Article

References (33)

1. Vendrell M, de Gracia J, Olveira C, Martínez MA, Girón R, Maíz L, et al. Diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol 2008; 44:629-40.
2. Barker AF, Bardana EJ. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988; 137:969-78. PMID: 3281531.
3. Martínez-García MA. Bronquiectasias: ¿todavía una enfermedad huérfana?. Arch Bronconeumol 2005; 41:407-9.
4. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12:205-9.
5. Säynäjäkangas O, Keistinen T, Tuuponen T, Kivelä SL. Bronchiectasis in Finland: Trends in hospital treatment. Respir Med 1997; 91:395-398. PMID: 9327038.
6. Twiss J, Metcalfe R, Edwards E, Byrnes C. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005; 90: 737-740. PMID: 15871981.
7. Hospital Episode Statistics 2002-2003. Departmentof Health. NHLBI. UK; 203, 2004.
8. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-Associated hospitalizations in de United States, 1993-2006. Chest 2010; 138:944-9. doi:10.1378/chest.10-0099 PMID: 20435655.
9. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142:432-9. PMID: 22302301.
10. Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013; 11:299-304. doi:10.1007/s40258-013-0027-zPMID: 23580074.
11. Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-Associated hospitalizations in Germany, 2005-2011: A population-based study of disease urden and trends. PLoS One 2013; 8:e71109. doi:10.1371/journal.pone.0071109 PMID: 23936489.
12. Lara B, Morales P, Blanco I, Vendrell M, de Gracia Roldán J, Monreal M, et al. Registros de enfermedades respiratoriasen España: fundamentos y organización. Arch Bronconeumol.2011; 47:389-96.
13. Ministerio de Empleo y Seguridad Social. Explotación estadística del Conjunto Mínimo Básico de Datos Hospitalarios. Nota metodológica. Normaestatal. [www.msssi.gob.es/estadEstudios/estadisticas/docs/NORMAGRD2011/norma-estatal-2011-notas-metod.pdf.].
14. Instituto Nacional de Estadística (INE). Population estimates. [www.ine.es].
15. Instituto Nacional de la Salud. CMBD Insalud. Análisis de los GRDs. Año 2000. [www.ingesa.msc.es/estadEstudios/documPublica/cmbd2000.htm.].
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9. PMID: 1607900.
17. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19:335-51. PMID: 10649300.
18. Joinpoint Regression Program. Version 4.0.4. Statistical Methodology and Applications Branch, Surveillance Research program, National Cancer Institute;May 2013.
19. Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur Respir J 2016; 47:186-93. doi:10.1183/13993003.01033-2015 PMID: 26541539.
20. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004; 8:691-702. PMID: 15182138.
21. Goeminne PC, De Soyza A. Bronchiectasis: how to be an orphan with many parents. Eur Respir J 2016; 47:10-3. doi:10.1183/13993003.01567-2015 PMID: 26721955.
22. MartínezGarcía MA, Soler Cataluña JJ. EPOC y bronquiectasias. Arch Bronconeumol 2010; 46 (Supl 3):11-7.
23. Martínez García MA, Soler Cataluña JJ, Donat Sanz, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140:1130- 7. doi:10.1378/chest.10-1758PMID: 21546440.
24. Patel IS, Vlahos I, Wilkinson TMA, Lloyd Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400-7. PMID: 15130905.
25. Donat Y, MartínezGarcía MA, Soler Cataluña JJ, Perpiná Tordera M, Román Sánchez P. Prevalencia de bronquiectasias y su impacto clínico-funcional en pacientes con enfermedad pulmonar obstructiva crónica moderado-grave. Arch Bronconeumol 2008; 44:60.
26. García Vidal C, Almagro P, Romani V, Rodríguez Carballeira M, Cuchi E, Canales L, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbations: A prospective study. Eur Respir J 2009; 34:1072-8. doi:10.1183/09031936.00003309 PMID: 19386694.
27. MartínezGarcía MA, de la Rosa D, Soler Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, et al. Prognostic value of bronchiectasis in patients with moderate-To-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:823-31. doi: 10.1164/rccm.201208-1518OC PMID: 23392438.
28. Joish VN, Spilsbury Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non-cystyc fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013; 11:299-304. doi:10.1007/s40258-013-0027-zPMID: 23580074.
29. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006; 28:974-9. PMID: 16899482.
30. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132:1565-72. PMID: 17998359.
31. Goeminne PC, Scheers H, Decraene A, Seys S and Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: A retrospective crosssectional analysis of CT diagnosed bronchiectatic patients. Respiratory Research 2012: 13:21. doi:10.1186/1465-9921-13-21 PMID: 22423975.
32. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010; 104:981-5. doi:10.1016/j.rmed.2010.02.022 PMID: 20303725.
33. Instituto Nacional de la Salud. Conjunto Mínimo Básico de Datos. Hospitales del INSALUD 2001. [www.ingesa.msc.es/estadEstudios/documPublica/pdf/CMBD-2001.pdf.].